Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review

Cobo‐Ibáñez, Tatiana; Loza-Santamaría, Estíbaliz; Pego-Reigosa, José María; Marquès, Alejandro Olivé; Rúa-Figueroa, Íñigo; Fernández‐Nebro, Antonio; Cáliz, Rafael; Longo, Francisco; Muñóz-Fernández, Santiago

doi:10.1016/j.semarthrit.2014.04.002

Cited by 108 publications

(77 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 In this case a satisfactory response solely due to Rituximab has been observed even in an advanced life threatening nephropathy situation. This is obvious that potential role of Rituximab as an immuno modulator cannot be left aside.…”

Section: Discussionmentioning

confidence: 60%

A case of complicated bullous systemic lupus erythematosus managed with Rituximab

Chakraborty¹,

Ghosh²,

Ghosh³

et al. 2017

AMJ

View full text Add to dashboard Cite

Skin Involvement is seen in nearly 76 per cent of Systemic lupus erythematosus (SLE) patients, but bullous lesion however accounts for less than one per cent of cutaneous manifestation of lupus erythematosus. A 21-year-old female presented with fever, polyarthalgia and vesicobullous skin lesion and acute renal failure. Clinico-pathological evaluation imparted that she was having bullous systemic lupus erythematosus (BSLE) with lupus nephritis. She was put on rituximab after initial resuscitation. She responded dramatically with resolution of skin lesion and recovery from acute renal failure. She was followed up for one year without complication with stable disease course.

show abstract

Section: Discussionmentioning

confidence: 60%

A case of complicated bullous systemic lupus erythematosus managed with Rituximab

Chakraborty¹,

Ghosh²,

Ghosh³

et al. 2017

AMJ

View full text Add to dashboard Cite

show abstract

“…13 However, it has also been suggested that RTX can only be recommended for organ-specific manifestations of SLE, such as arthritis and autoimmune thrombocytopenic purpura and thrombocytopenia. [14][15][16] The incidence of serious infections has been estimated to be 6.6/100-12.6/100 patient-years. The most common side effects associated with RTX include; mild infusion reactions (35%), neutropenia and infections (10%).…”

Section: Discussionmentioning

confidence: 99%

Atypical Multiple Cutaneous Ulcers in A Patient with Systemic Lupus Erythematosus Treated with Rituximab: Case Report

Üstüner¹,

Özdemır²,

Balevi³

2016

Turkiye Klinikleri J Dermatol

View full text Add to dashboard Cite

“…Ezeonyeji and Isenberg have also demonstrated that early treatment of SLE with a combination regimen of rituximab and cyclophosphamide may allow for a steroid-free drug regimen in managing lupus [23], although Li et al showed that cyclophosphamide with rituximab for induction therapy of lupus nephritis may not provide any added improvement than rituximab alone [24]. A recent systematic review also demonstrates the efficacy of rituximab [25]. Our study demonstrates significant levels of steroid reduction after rituximab therapy and very low levels of serious adverse events when rituximab is used with lower doses of oral steroids than were used in clinical trials.…”

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus

et al. 2015

View full text Add to dashboard Cite

In contrast to randomised clinical trials, open-label studies have suggested that B cell depletion by a course of rituximab is associated with a significant clinical benefit. Our aim was to assess the safety and efficacy of rituximab in 15 refractory lupus patients, particularly those with more than one course of therapy. Disease activity was measured by the classic British Isles Lupus Assessment Group (BILAG) index, anti-DNA antibodies and complement levels. We assessed immunoglobulin levels, functional antibodies and serious adverse events. The mean patient age ± SD was 37.9 ± 7.2 years and mean disease duration was 8.5 ± 3.3 years; 46% were Afro-Caribbean, 27% South Asian, 20% Caucasian and 7% others. Twelve patients responded by 6 months; six avoided major flare for >1 year. Complete absence of disease activity (BILAG D/E) lasted for 5.5 (SD 3.8) months and 4.8 (SD 3.6) months after the first (n = 15) and second (n = 9) rituximab course, respectively. The mean 6-month reduction in daily prednisolone was 10.4 (SD 11.4) mg/day and 10.7 (SD 9.3) mg/day from baseline after the first and second course, respectively. Patients with low C3/C4 normalised their C3 by 6 months. Most patients with raised anti-dsDNA normalised after rituximab courses. Serious adverse events only occurred after more than four courses of rituximab. Rituximab was safe and efficacious for treating patients with refractory systemic lupus erythematosus (SLE) and was associated with significant steroid reduction, but more than four courses of rituximab was associated with an increased risk of serious infection in two patients.

show abstract

Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review

Cited by 108 publications

References 31 publications

A case of complicated bullous systemic lupus erythematosus managed with Rituximab

A case of complicated bullous systemic lupus erythematosus managed with Rituximab

Atypical Multiple Cutaneous Ulcers in A Patient with Systemic Lupus Erythematosus Treated with Rituximab: Case Report

The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus

Contact Info

Product

Resources

About